<p><strong>CYP3A Inhibitors</strong>: Co-administration with strong and moderate CYP3A inhibitors should be avoided. If a moderate CYP3A inhibitor must be used, Ibrutinib dose should be reduced&nbsp;<br />
<br />
<strong>CYP3A Inducers</strong>: Co-administration with strong CYP3A inducers should be avoided</p>